Altering Brain Barrier to attack Glioblastomas

A recent study demonstrated as glioblastoma cells can sequester the cerebral blood cells during the early stages of the progression of the disease and damage to the protective barrier of the brain. This discovery could lead to new therapeutic strategies designed to induce tumor death, thanks to treatments that are able to reach these damaged cells in the earliest stages of enferemedad.
Glioblastoma is a highly aggressive type of brain tumor with few treatment options. These tumors progress rapidly and are difficult to treat because the brain has a barrier that prevents the entry of foreign substances.
The blood-brain barrier is designed to stem the flow of harmful material in the brain and regulate the transport of large molecules between the bloodstream and the brain. A key component of the blood-brain barrier tight junctions are (o tigh junctions) that create a seal between the endothelial blood cells. Astrocytes are another component of the barrier and these cells can regulate the connections between endothelial cells as well as release specific chemicals that cause expansion or contraction of blood cells, regulating blood flow to the brain.
The publication of Dr. Harald Sontheimer in Nature Communications studies the interaction between glioblastoma, brain astrocytes and blood vesicles by using sophisticated animal model for identifying the migration of tumor cells. In the publication is described as glioblastoma cells surrounding the tumor are located between astrocytes and the surface of blood vesicles. These cells appear to use vesicles as a highway to travel long distances in the brain.
Also, the results suggest as control glioblastoma cells to blood cells, disturbing the tight junctions and causing a breach in the blood-brain barrier during the early stages of tumor development.
This finding would allow the use of treatments with anti-invasive agents in therapy to combat glioblastomas. Besides the identification of gaps in the blood brain barrier allow precise release of drugs to attack tumors in the early stages.